Special CHM Conversation: Second-Line ER+/HER2- mBC with Drs. Seth Wander & Paolo Tarantino

Responses to Vepdegestrant After an Oral SERD with Drs. Jason Mouabbi & Erika Hamilton

Endocrine Therapy After ADCs with Drs. Jason Mouabbi & Erika Hamilton

Vepdegestrant Safety & Tolerability with Drs. Jason Mouabbi & Erika Hamilton

VERITAC-2, EMERALD & EMBER-3 Trial Designs Explained with Drs. Jason Mouabbi & Erika Hamilton

Oral SERDs and PROTACs in ESR1-Mutated Breast Cancer with Drs. Jason Mouabbi & Erika Hamilton

When and How to Test for ESR1 Mutations with Drs. Jason Mouabbi & Erika Hamilton

Neoadjuvant & Adjuvant T-DXd in HER2+ Breast Cancer with Drs. Paolo Tarantino & Seth Wander

T-DXd Supportive Care: ILD & Nausea with Drs. Paolo Tarantino & Seth Wander

Progression on First-Line T-DXd: Sequencing & Rechallenge with Drs. Paolo Tarantino & Seth Wander

PATINA & HER2CLIMB-05 Maintenance with Drs. Paolo Tarantino & Seth Wander

DB09 Deep Response: How Long to Give T-DXd Plus Pertuzumab? with Drs. Paolo Tarantino & Seth Wander

First-Line T-DXd Plus Pertuzumab: Efficacy & Selection with Drs. Paolo Tarantino & Seth Wander

ESR1-Mutated Breast Cancer: Oral SERDs and Vepdegestrant with Drs. Jason Mouabbi & Erika Hamilton

T-DXd Across HER2+ Breast Cancer with Drs. Paolo Tarantino & Seth Wander

T-DXd Tolerability: Managing Nausea & ILD with Drs. Ruta Rao & Irene Kang

Early-Stage HER2+ BC: Where Does T-DXd Fit Best? with Drs. Ruta Rao & Irene Kang

DB09 Response Data: How Long to Give T-DXd Plus Pertuzumab? with Drs. Ruta Rao & Irene Kang

HER2+ MBC Maintenance: Where Do PATINA & HER2CLIMB-05 Fit? with Drs. Ruta Rao & Irene Kang

DB09 & Patient Selection: T-DXd Plus Pertuzumab or THP? with Drs. Ruta Rao & Irene Kang

DB11 & Neoadjuvant T-DXd: Who Benefits Most? with Drs. Ruta Rao & Irene Kang

T-DXd in HER2+ Breast Cancer with Drs. Ruta Rao & Irene Kang

Early-Stage to Metastatic: Can We Reuse T-DXd? with Drs. Jason Mouabbi & Neil Iyengar

PATINA & HER2CLIMB-05: Maintenance Strategies in HER2+ mBC with Drs. Jason Mouabbi & Neil Iyengar

Managing T-DXd Nausea to Help Patients Stay on Therapy with Drs. Jason Mouabbi & Neil Iyengar

T-DXd Plus Pertuzumab: How Long to Continue? with Drs. Jason Mouabbi & Neil Iyengar

Response Data from T-DXd Plus Pertuzumab in DB09 with Drs. Jason Mouabbi & Neil Iyengar

DB09 Design & Efficacy in First-Line HER2+ mBC with Drs. Jason Mouabbi & Neil Iyengar

T-DXd Plus Pertuzumab in First-Line HER2+ Breast Cancer with Drs. Jason Mouabbi & Neil Iyengar

BTK Inhibition in BTKi-Naïve Relapsed CLL with Drs. Kerry Rogers, William Wierda & Catherine Coombs

Choosing a Fixed-Duration Approach in CLL with Drs. Kerry Rogers, William Wierda & Catherine Coombs

Choosing: Acalabrutinib or Zanubrutinib? with Drs. Kerry Rogers, William Wierda & Catherine Coombs

When to Consider Continuous BTK Inhibition with Drs. Kerry Rogers, William Wierda & Catherine Coombs

BTK Inhibitor Combinations in Frontline CLL with Drs. Kerry Rogers, William Wierda & Catherine Coomb

Lifestyle & Fixed-Duration CLL Therapy with Drs. Kerry Rogers, William Wierda & Catherine Coombs

Navigating First-Line CLL Treatment with Drs. Kerry Rogers, William Wierda & Catherine Coombs

Real-World Capivasertib Use with Dr. Ruta Rao & Dr. Azadeh Nasrazadani

Managing Capivasertib Toxicity with Drs. Ruta Rao & Azadeh Nasrazadani

PIK3CA-Targeted Therapy After CDK4/6 in HR+ Breast Cancer with Drs. Ruta Rao & Azadeh Nasrazadani

Co-mutations: Sequencing Therapy in ESR1/PIK3CA Patients with Drs. Ruta Rao & Azadeh Nasrazadani

When to Repeat Biomarker Testing in HR+ mBC with Drs. Ruta Rao & Azadeh Nasrazadani

Choosing 2L Therapy After CDK4/6 Inhibitors with Drs. Ruta Rao & Azadeh Nasrazadani

Why First-Line HER2+ Therapy Selection Matters with Drs. Sonya Reid & Shruti Singh

What Comes After First-Line T-DXd? — with Drs. Sonya Reid & Shruti Singh

Continuous T-DXd and the Question of Maintenance—with Drs. Sonya Reid & Shruti Singh

Managing T-DXd Side Effects with Drs. Sonya Reid & Shruti Singh

T-DXd Rechallenge After Early-Stage Treatment with Drs. Sonya Reid & Shruti Singh

Discussing CLEOPATRA and DESTINY-Breast09 with Drs. Sonya Reid & Shruti Singh

Evolving First-Line HER2+ Metastatic Breast Cancer with Drs. Sonya Reid & Shruti Singh

This Moment In Medicine: First-Line HER2+ Metastatic Breast Cancer with Dr. Mothaffar Rimawi

This Moment in Medicine: T-DXd in Early HER2+ BC with Dr. Michelina Cairo

This Moment in Medicine: Rethinking Adjuvant Therapy in ER+ Breast Cancer with Dr. Akshjot Puri

This Moment in Medicine: First-Line ADCs in Metastatic TNBC with Dr. Senthil Damodaran

Do BRCA Patients Benefit from ADCs? | This Moment in Medicine

Oncotype or Prosigna — Which Genomic Test Is More Informative? | This Moment in Medicine

Neoadjuvant or Adjuvant T-DXd? | This Moment in Medicine

Navigating ‘Discordant’ Breast Cancer Genomic Assays | This Moment in Medicine

Gedatolisib Triplet Yields Impressive PFS Curves in HR+ mBC | This Moment in Medicine

How the EMERALD Trial & Elacestrant Changed ER-Positive mBC | This Moment in Medicine

This Moment in Medicine | Breast Cancer Updates That Will Change Clinical Practice